Atlas of Genetics and Cytogenetics in Oncology and Haematology


Home   Genes   Leukemias   Solid Tumours   Cancer-Prone   Deep Insight   Case Reports   Journals   Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA


do you wish to send a case report ?


CASE REPORTS in HAEMATOLOGY
(Paper co-edited with the European LeukemiaNet)
t(4;12)(q11;p13) in an acute myeloid leukemia without maturation with myelodysplasia
 
Written2005-09Jean Philippe Rault
CHR Bon Secours Géné
Clinics
Age and sex : 67 year(s) old male patient.
Previous History : no preleukemia
no previous malignant disease
no inborn condition of note
Organomegaly : no hepatomegaly ; no splenomegaly ; no enlarged lymph nodes ; no central nervous system involvement
Blood
WBC : 3 x 109/L (6); Hb : 8 g/dL (6); platelets : 151 x 109/L; blasts : 56 % .
Bone marrow : Cellularity fewer than usual. Rare megakaryocytes, presence of micromegakaryocytes. Infiltration by blasts at a level of 58% with myeloid features. Dysgranulopoiesis > 10 % of non erythoblastic cells
Cyto pathology classification
Immunophenotype : CD34 (85%), HLA DR (91%) and myeloid cluster: CD11c (7%), CD13 (97%), CD13c (99%), CD33 (98%), CD117 (81%), MPO 5% and only one lymphoid cluster CD7 (87%). Conclusion: immature myeloid population. Phenotype FAB M0
Rearranged Ig Tcr : Not done
Pathology : Secondary Acute Respiratory desease due to a bilateral alveolar pneumopathy on June 2005, without suitable microbiological data, following an aplasia phase with fever at D+16 ( chemotherapy induction step)
Electron microscopy : No
Precise diagnosis : AML type Mo with myelodysplasia
Survival
Date of diagnosis: 04-2005
Treatment : LAM SA 2002 Protocol. Idarubicine: 15mg per day from J1 to J5 / Aracytine: 180 mg per day from J1 to J7 / Belustine: 360 mg only at J1 then Aracytine and Idarubicine each three month during 15 days (6 cures).
Complete remission : None
Treatment related death : No
Relapse : No
Status : Alive 08-2005
Survival : 5 month(s)
Karyotype
Sample : Bone marrow ; culture time : 24/48 h ; banding : R
Results : 46, XY, t(4;12)(q11;p13.1) [27] / 46, XY [3]
Karyotype at relapse : No relapse
t(4;12)(q11;p13.1) R-banding
Comments
No AML/ETO t(8;21)(q22;q22) translocation, no split of MLL performed by FISH analysis
Internal links
Atlas Cardt(4;12)(q11-q21;p13)
Case ReportThe rare t(4;12)(q11;p13) in an elderly patient with de novo AML with multilineage dysplasia co-expressing stem cell markers
Bibliography
Isochromosome (17)(q10) and translocation (4;12)(q12;p13) in a child with acute myeloid leukemia.
Nathan PC, Chun K, Abdelhaleem M, Malkin D
Cancer genetics and cytogenetics. 2001 ; 131 (1) : 82-85.
PMID 11734325
 

Citation

This paper should be referenced as such :
Free journal version : [ pdf ]   [ DOI ]
On line version : http://AtlasGeneticsOncology.org/Reports/0412RaultID100014.html

© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Tue Mar 14 13:58:21 CET 2017


Home   Genes   Leukemias   Solid Tumours   Cancer-Prone   Deep Insight   Case Reports   Journals   Portal   Teaching   

For comments and suggestions or contributions, please contact us

jlhuret@AtlasGeneticsOncology.org.